Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
187 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Dengue - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Dengue - Pipeline Review, H1 2015', provides an overview of the Dengue's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dengue and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Dengue - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dengue and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Dengue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Dengue pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Dengue - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Dengue pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Dengue Overview 9 Therapeutics Development 10 Pipeline Products for Dengue - Overview 10 Pipeline Products for Dengue - Comparative Analysis 11 Dengue - Therapeutics under Development by Companies 12 Dengue - Therapeutics under Investigation by Universities/Institutes 16 Dengue - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Unknown Stage Products 21 Dengue - Products under Development by Companies 22 Dengue - Products under Investigation by Universities/Institutes 26 Dengue - Companies Involved in Therapeutics Development 28 Agilvax, Inc. 28 AltraVax Inc. 29 Arbovax, Inc. 30 BioDiem Ltd 31 Biotron Limited 32 Cocrystal Pharma, Inc. 33 Codagenix, Inc. 34 FIT Biotech Oyj 35 GlaxoSmithKline plc 36 Humabs BioMed SA 37 Immunovaccine, Inc. 38 Johnson & Johnson 39 Kineta, Inc. 40 MacroGenics, Inc. 41 Medivir AB 42 Merck & Co., Inc. 43 Molplex Ltd. 44 Myelo Therapeutics GmbH 45 NanoViricides, Inc. 46 Panacea Biotec Limited 47 PaxVax 48 Prosetta Antiviral Inc. 49 RFS Pharma, LLC 50 Sanofi Pasteur SA 51 Sarepta Therapeutics, Inc. 52 SIGA Technologies, Inc. 53 SKAU Vaccines ApS 54 Takeda Pharmaceutical Company Limited 55 TechnoVax, Inc. 56 Themis Bioscience GmbH 57 United Therapeutics Corporation 58 VaxInnate Corporation 59 Visterra, Inc. 60 Dengue - Therapeutics Assessment 61 Assessment by Monotherapy Products 61 Assessment by Target 62 Assessment by Mechanism of Action 64 Assessment by Route of Administration 66 Assessment by Molecule Type 68 Drug Profiles 70 BG-323 - Drug Profile 70 celgosivir hydrochloride - Drug Profile 71 dengue (tetravalent) vaccine - Drug Profile 72 dengue (tetravalent) vaccine - Drug Profile 73 dengue (tetravalent) vaccine 4 - Drug Profile 74 dengue [DENV-2] vaccine - Drug Profile 75 dengue [rDEN1delta30, rDEN2/4delta30(ME), rDEN3delta30/31 and rDEN4delta30] (tetravalent) vaccine - Drug Profile 76 dengue [serotypes 1,2,3,4] (tetravalent) vaccine - Drug Profile 77 dengue fever vaccine - Drug Profile 80 dengue vaccine - Drug Profile 81 dengue vaccine - Drug Profile 82 dengue vaccine - Drug Profile 83 dengue vaccine - Drug Profile 85 dengue vaccine - Drug Profile 86 dengue vaccine - Drug Profile 87 dengue vaccine - Drug Profile 88 dengue vaccine - Drug Profile 89 dengue vaccine (DENV-2) - Drug Profile 90 dengue vaccine (tetravalent) - Drug Profile 91 dengue vaccine (tetravalent) - Drug Profile 93 dengue vaccine (tetravalent) - Drug Profile 94 dengue vaccine [DEN-1 and DEN-2] - Drug Profile 95 dengue vaccine [DEN-2] - Drug Profile 96 dengue vaccine 3 - Drug Profile 97 dengue vaccine 4 - Drug Profile 99 dengue vaccines - Drug Profile 100 dengue virus vaccine - Drug Profile 101 dengue virus vaccine (tetravalent) - Drug Profile 102 DengueCide - Drug Profile 103 DENV-1 PIV - Drug Profile 104 DiTU - Drug Profile 105 DV-2-DeltaGVII - Drug Profile 106 DV-2-DeltaLIG - Drug Profile 107 DV-2-G460P - Drug Profile 108 ETX-101 - Drug Profile 110 GBV-001 - Drug Profile 111 GBV-006 - Drug Profile 112 GBV-012 - Drug Profile 113 GREDEN/V1-4 - Drug Profile 114 LCTA-949 - Drug Profile 115 LVM-142 - Drug Profile 116 modipafant - Drug Profile 117 Monoclonal Antibodies for Infectious Disease - Drug Profile 118 Monoclonal Antibodies to Inhibit prM and E Proteins for Dengue - Drug Profile 119 Monoclonal Antibody for Dengue - Drug Profile 120 Monoclonal Antibody for Dengue - Drug Profile 121 Myelo-001 - Drug Profile 122 PAV-866 - Drug Profile 123 Recombinant Peptide to Inhibit Dengue Protease for Dengue - Drug Profile 124 RNAi Oligonucleotide for Dengue - Drug Profile 125 rOAS - Drug Profile 126 RS-1137 - Drug Profile 127 RS-1142 - Drug Profile 128 RS-1145 - Drug Profile 129 RS-930 - Drug Profile 130 RS-961 - Drug Profile 131 Small Molecule for Dengue - Drug Profile 132 Small Molecule for Dengue - Drug Profile 133 Small Molecule Inhibitors of NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile 134 Small Molecule to Inhibit NS3 Protease for Dengue - Drug Profile 135 Small Molecules for Dengue - Drug Profile 136 Small Molecules for Dengue - Drug Profile 137 Small Molecules Inhibiting M Protein for Dengue - Drug Profile 138 Small Molecules to Activate AMPK for Dengue - Drug Profile 139 Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile 140 Small Molecules to Inhibit Furin for Dengue - Drug Profile 142 Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile 143 Small Molecules to Inhibit NS4b for Dengue - Drug Profile 144 Small Molecules to Inhibit Protease for Dengue - Drug Profile 145 Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections - Drug Profile 146 Small Molecules to Inhibit Serine Protease for Viral Infections - Drug Profile 147 ST-148 - Drug Profile 148 ST-324 - Drug Profile 149 ST-610 - Drug Profile 150 Synthetic Peptides for West Nile Virus and Dengue Virus Infections - Drug Profile 151 TAK-003 - Drug Profile 152 TVX-005 - Drug Profile 154 UV-4B - Drug Profile 155 V-180 - Drug Profile 156 Viral PMO-X - Drug Profile 157 VIS-513 - Drug Profile 158 Dengue - Recent Pipeline Updates 159 Dengue - Dormant Projects 165 Dengue - Discontinued Products 167 Dengue - Product Development Milestones 168 Featured News & Press Releases 168 Appendix 180 Methodology 180 Coverage 180 Secondary Research 180 Primary Research 180 Expert Panel Validation 180 Contact Us 181 Disclaimer 181
List of Tables Number of Products under Development for Dengue, H1 2015 16 Number of Products under Development for Dengue - Comparative Analysis, H1 2015 17 Number of Products under Development by Companies, H1 2015 19 Number of Products under Development by Companies, H1 2015 (Contd..1) 20 Number of Products under Development by Companies, H1 2015 (Contd..2) 21 Number of Products under Investigation by Universities/Institutes, H1 2015 23 Comparative Analysis by Late Stage Development, H1 2015 24 Comparative Analysis by Clinical Stage Development, H1 2015 25 Comparative Analysis by Early Stage Development, H1 2015 26 Comparative Analysis by Unknown Stage Development, H1 2015 27 Products under Development by Companies, H1 2015 28 Products under Development by Companies, H1 2015 (Contd..1) 29 Products under Development by Companies, H1 2015 (Contd..2) 30 Products under Development by Companies, H1 2015 (Contd..3) 31 Products under Investigation by Universities/Institutes, H1 2015 32 Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 33 Dengue - Pipeline by Agilvax, Inc., H1 2015 34 Dengue - Pipeline by AltraVax Inc., H1 2015 35 Dengue - Pipeline by Arbovax, Inc., H1 2015 36 Dengue - Pipeline by BioDiem Ltd, H1 2015 37 Dengue - Pipeline by Biotron Limited, H1 2015 38 Dengue - Pipeline by Cocrystal Pharma, Inc., H1 2015 39 Dengue - Pipeline by Codagenix, Inc., H1 2015 40 Dengue - Pipeline by FIT Biotech Oyj, H1 2015 41 Dengue - Pipeline by GlaxoSmithKline plc, H1 2015 42 Dengue - Pipeline by Humabs BioMed SA, H1 2015 43 Dengue - Pipeline by Immunovaccine, Inc., H1 2015 44 Dengue - Pipeline by Johnson & Johnson, H1 2015 45 Dengue - Pipeline by Kineta, Inc., H1 2015 46 Dengue - Pipeline by MacroGenics, Inc., H1 2015 47 Dengue - Pipeline by Medivir AB, H1 2015 48 Dengue - Pipeline by Merck & Co., Inc., H1 2015 49 Dengue - Pipeline by Molplex Ltd., H1 2015 50 Dengue - Pipeline by Myelo Therapeutics GmbH, H1 2015 51 Dengue - Pipeline by NanoViricides, Inc., H1 2015 52 Dengue - Pipeline by Panacea Biotec Limited, H1 2015 53 Dengue - Pipeline by PaxVax, H1 2015 54 Dengue - Pipeline by Prosetta Antiviral Inc., H1 2015 55 Dengue - Pipeline by RFS Pharma, LLC, H1 2015 56 Dengue - Pipeline by Sanofi Pasteur SA, H1 2015 57 Dengue - Pipeline by Sarepta Therapeutics, Inc., H1 2015 58 Dengue - Pipeline by SIGA Technologies, Inc., H1 2015 59 Dengue - Pipeline by SKAU Vaccines ApS, H1 2015 60 Dengue - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 61 Dengue - Pipeline by TechnoVax, Inc., H1 2015 62 Dengue - Pipeline by Themis Bioscience GmbH, H1 2015 63 Dengue - Pipeline by United Therapeutics Corporation, H1 2015 64 Dengue - Pipeline by VaxInnate Corporation, H1 2015 65 Dengue - Pipeline by Visterra, Inc., H1 2015 66 Assessment by Monotherapy Products, H1 2015 67 Number of Products by Stage and Target, H1 2015 69 Number of Products by Stage and Mechanism of Action, H1 2015 71 Number of Products by Stage and Route of Administration, H1 2015 73 Number of Products by Stage and Molecule Type, H1 2015 75 Dengue Therapeutics - Recent Pipeline Updates, H1 2015 165 Dengue - Dormant Projects, H1 2015 171 Dengue - Discontinued Products, H1 2015 173
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
